Effects of Ligusticum porteri (Osha) Root Extract on Human Promyelocytic Leukemia Cells

Background: Ligusticum porteri roots have been traditionally used in folk medicine, but the scientific basis is unclear. Objective: To investigate the cytotoxicity, antioxidant, and immunomodulatory effects of L. porteri root extract on human promyelocytic leukemia (HL‑60) cells and H₂O2‑induced oxidative damaged HL‑60 cells. Materials and Methods: HL‑60 cells were incubated with different concentrations of root extract, and cells were harvested for viability assays on day 3 and 7. Cytokine levels (interferon‑gamma [IFN‑γ], interleukin‑2 [IL‑2], and interleukin-10 [IL‑10]) and antioxidant indexes (malondialdehyde [MDA], reduced glutathione [GSH], superoxide dismutase [SOD], and catalase [CAT]) in H₂O₂‑induced‑stressed HL‑60 were measured after 2 days. Results: The viability of HL‑60 challenged with H₂O₂ declined by 42% compared to unstressed cells. After 7 days of incubation with 200 or 400 μg/mL L. porteri, the viability of HL‑60 cells was two‑fold higher than the control. Stressed HL‑60 cells treated with 100, 200, and 400 μg/mL L. porteri reduced the lipid peroxidation by 12%–13%. We noted an increase in GSH levels, SOD and CAT activities in stressed HL‑60 supplemented with 400 μg/mL root extract. Treatment with 400 μg/mL L. porteri significantly (P < 0.05) increased IFN‑γ and IL‑2 in H₂O₂‑challenged cells. Conclusion: Our data do not support the use of the extract as an antiproliferation and differentiation therapy for acute promyelocytic leukemia. The protective function of L. porteri root extract against oxidative stress could occur through increasing GSH and higher expression of antioxidant enzymes.